Improving phase II oncology trials using best observed RECIST response as an endpoint by modelling continuous tumour measurements. (2017)
Attributed to:
Developing efficient perpetual platform trials to study multiple treatments and multiple biomarkers
funded by
MRC
Abstract
No abstract provided
Bibliographic Information
Digital Object Identifier: http://dx.doi.org/10.17863/cam.21357
Publication URI: https://www.repository.cam.ac.uk/handle/1810/274249
Type: Journal Article/Review